A new HDAC inhibitor called CS3003 is now in a Phase I study in China for multiple myeloma patients. It is considered to be a HDAC6 inhibitor which is different from the pan-HDAC inhibitors approved in the US for myeloma like panobinostat.
Dr. Jon Wang, Chief Scientific Officer of CStone said:
“The selective inhibition of HDAC6 has the potential to produce better efficacy in multiple myeloma either as monotherapy or in combination with current standard of cares. Furthermore, preclinical data and early clinical studies of similar products in the same class have indicated that CS3003 has better safety profile than pan-HDAC inhibitors and the potential to develop combination therapies with immune checkpoint inhibitors for the treatment multiple types of solid tumors.”
This HDAC inhibitor has shown better impact and improved safety results over pan-HDAC inhibitors. It could also be combined with PD-L1 antibodies to expand the power of checkpoint inhibitors.
The work is early and it will be interesting to see how it progresses through clinical studies.